Search research articles
Contact Us
Filters
Showing results (61-70 of 95) with videos related to
Page
of 10
Sort By:
The Lancet. Oncology
|
May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Karim Fizazi, Michael J Morris, Neal D Shore, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2025
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial
Adrien Rousseau, Maryam Karimi, Stefan Michiels, et al.
The Lancet. Oncology
|
February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
Antoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
Clinical Genitourinary Cancer
|
October 4, 2018
Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study
Aline Guillot, Charlotte Joly, Philippe Barthélémy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
Lucie Meynard, Derek Dinart, Blandine Delaunay, et al.
Minerva Urology and Nephrology
|
March 11, 2022
Perioperative outcomes after radical prostatectomy: does the surgical approach change the impact of hospital volume? A nationwide analysis
Michael Baboudjian, Bastien Gondran-Tellier, Annabelle Grabia, et al.
European Urology Oncology
|
November 19, 2024
Anatomic Factors Associated with Complications After Radical Prostatectomy: A Systematic Review and Meta-analysis
Arthur Peyrottes, Charles Dariane, Michael Baboudjian, et al.
NEJM Evidence
|
February 6, 2024
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
Karim Fizazi, Alice Bernard-Tessier, Guilhem Roubaud, et al.
The New England Journal of Medicine
|
September 21, 2020
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain, Joaquin Mateo, Karim Fizazi, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 95) with videos related to
Sort By:
Page
of 10
The Lancet. Oncology
|
May 29, 2025
Health-related quality of life, pain, and symptomatic skeletal events with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Karim Fizazi, Michael J Morris, Neal D Shore, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2025
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial
Adrien Rousseau, Maryam Karimi, Stefan Michiels, et al.
The Lancet. Oncology
|
February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
Antoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
Clinical Genitourinary Cancer
|
October 4, 2018
Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study
Aline Guillot, Charlotte Joly, Philippe Barthélémy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
Lucie Meynard, Derek Dinart, Blandine Delaunay, et al.
Minerva Urology and Nephrology
|
March 11, 2022
Perioperative outcomes after radical prostatectomy: does the surgical approach change the impact of hospital volume? A nationwide analysis
Michael Baboudjian, Bastien Gondran-Tellier, Annabelle Grabia, et al.
European Urology Oncology
|
November 19, 2024
Anatomic Factors Associated with Complications After Radical Prostatectomy: A Systematic Review and Meta-analysis
Arthur Peyrottes, Charles Dariane, Michael Baboudjian, et al.
NEJM Evidence
|
February 6, 2024
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
Karim Fizazi, Alice Bernard-Tessier, Guilhem Roubaud, et al.
The New England Journal of Medicine
|
September 21, 2020
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain, Joaquin Mateo, Karim Fizazi, et al.
Page
of 10